Drug Approval | April 28, 2025
CuraTeQ Biologics receives positive opinion for biosimilar Dazublys from EMA
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC) aims to accelerate the digital transformation of CMC development and manufacturing approaches
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
This registration authorizes Nureca Technologies to continue manufacturing and exporting asuite of medical devices to the United States
This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance
Sharma brings a wealth of expertise in optimizing manufacturing processes for fermentation-based APIs and sterile injectables
Data highlight ambition to transform prevention and treatment for serious bacterial infections and develop novel preventative strategies for respiratory viral infections
In light of the contributions of these three institutes, it was decided to organize a CSIR Startup Conclave in Hyderabad. The event, scheduled for April 22–23, 2025
Subscribe To Our Newsletter & Stay Updated
